Your bag is empty.
GLP-3 is an investigational triple-hormone-receptor agonist ("triple G") targeting GLP-1, GIP, and glucagon receptors. Clinical trials show it delivers exceptional weight loss of up to 24% to 28% of body weight, deep abdominal and liver fat reductions, and improved blood sugar control.
Major Health Benefits
Substantial weight loss: Trials demonstrate average weight reduction surpassing 24–28% over extended dosing schedules, outperforming many dual or single-agonist alternatives.
Increased energy expenditure: Unlike drugs relying solely on appetite suppression, the inclusion of glucagon receptor activation helps ramp up calorie burning and fat metabolism.
Liver fat reduction: Early studies show dramatic decreases (up to 81–86%) in hepatic fat for individuals with metabolic-associated fatty liver disease.
Blood sugar and lipid control: Helps lower HbA1c in type 2 diabetes, aids prediabetes remission, and improves overall cardiovascular and blood lipid profiles.
Joint pain relief: Secondary trial measures noted decreased knee osteoarthritis pain and physical strain due to lowered body weight.